Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38 ; volume:17 ; number:1 ; day:3 ; month:11 ; year:2017 ; pages:1-13 ; date:12.2017
BMC cancer ; 17, Heft 1 (3.11.2017), 1-13, 12.2017
- Creator
-
Gohr, Katharina
- Contributor
-
Hamacher, Alexandra
Engelke, Laura H.
Kassack, Matthias U.
SpringerLink (Online service)
- DOI
-
10.1186/s12885-017-3695-5
- URN
-
urn:nbn:de:101:1-2018090514134314025306
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gohr, Katharina
- Hamacher, Alexandra
- Engelke, Laura H.
- Kassack, Matthias U.
- SpringerLink (Online service)
Other Objects (12)
PD-L1 enhanced cisplatin resistance in non-small cell lung cancer through PI3K/AKT/mTOR
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer
Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells
Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer
MNAT1 promotes proliferation and the chemo-resistance of osteosarcoma cell to cisplatin through regulating PI3K/Akt/mTOR pathway
Targeting the PI3K/AKT/MTOR pathway in KSHV-associated cancers
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
Linc00707 regulates autophagy and promotes the progression of triple negative breast cancer by activation of PI3K/AKT/mTOR pathway
Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K/Akt/mTOR pathway and cancer stem cells
Multiple outcomes for PI3K/Akt/mTOR targeting in non-Hodgkin lymphoma
PD-L1 enhanced cisplatin resistance in non-small cell lung cancer through PI3K/AKT/mTOR
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer
Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells
Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer
MNAT1 promotes proliferation and the chemo-resistance of osteosarcoma cell to cisplatin through regulating PI3K/Akt/mTOR pathway
Targeting the PI3K/AKT/MTOR pathway in KSHV-associated cancers
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
Linc00707 regulates autophagy and promotes the progression of triple negative breast cancer by activation of PI3K/AKT/mTOR pathway
Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K/Akt/mTOR pathway and cancer stem cells
Multiple outcomes for PI3K/Akt/mTOR targeting in non-Hodgkin lymphoma
PD-L1 enhanced cisplatin resistance in non-small cell lung cancer through PI3K/AKT/mTOR
Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer
Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells
Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer
MNAT1 promotes proliferation and the chemo-resistance of osteosarcoma cell to cisplatin through regulating PI3K/Akt/mTOR pathway
Targeting the PI3K/AKT/MTOR pathway in KSHV-associated cancers
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
Linc00707 regulates autophagy and promotes the progression of triple negative breast cancer by activation of PI3K/AKT/mTOR pathway
Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K/Akt/mTOR pathway and cancer stem cells